Optimum modification for the highest cytotoxicity of cationized ribonuclease

被引:37
作者
Futami, J [1 ]
Nukui, E [1 ]
Maeda, T [1 ]
Kosaka, M [1 ]
Tada, H [1 ]
Seno, M [1 ]
Yamada, H [1 ]
机构
[1] Okayama Univ, Dept Biosci & Biotechnol, Fac Engn, Grad Sch Nat Sci & Technol, Okayama 7008530, Japan
关键词
cationization; cytotoxicity; protein transduction; ribonuclease;
D O I
10.1093/oxfordjournals.jbchem.a003214
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cationization of a protein is considered to be a powerful strategy for internalizing a functional protein into cells. Cationized proteins appear to adsorb to the cell surface by electrostatic interactions, then enter the cell in a receptor- and transporter-independent fashion. Thus, in principle, all cell types appear to take up cationized proteins. Since ribonucleases (RNases) have a latent cytotoxic potential, cationized RNases could be useful cancer chemotherapeutics. In this study, we investigated the effect of the degree of cationization on the cytotoxicity of RNase A by modifying carboxyl groups with ethylenediamine. We found that there is an optimum degree of modification for cytotoxicity, in which 5 to 7 out of 11 carboxyl groups in RNase A are modified, toward MCF-7 and 3T3-SV-40 cells. More interestingly, the cytotoxicity of cationized RNase As correlates well with the value of [RNase activity] x [estimated concentration of RNase free from RNase inhibitor], mimicking the practical enzymatic activity of cationized RNase As in cytosol. The results indicate that cationization of a protein to an optimum level is important for maintaining protein function in the cytosol. Sophisticated protein cationization techniques will help to advance protein transduction technology.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 56 条
  • [31] NEWTON DL, 1992, J BIOL CHEM, V267, P19572
  • [32] NITTA K, 1994, CANCER RES, V54, P920
  • [33] ENHANCED CELLULAR UPTAKE AND IN-VIVO BIODISTRIBUTION OF A MONOCLONAL-ANTIBODY FOLLOWING CATIONIZATION
    PARDRIDGE, WM
    KANG, YS
    YANG, J
    BUCIAK, JL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (08) : 943 - 948
  • [34] Pardridge WM, 1998, J PHARMACOL EXP THER, V286, P548
  • [35] ENHANCED ENDOCYTOSIS AND ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVITY OF ANTI-REV ANTIBODIES AFTER CATIONIZATION
    PARDRIDGE, WM
    BICKEL, U
    BUCIAK, J
    YANG, J
    DIAGNE, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) : 55 - 61
  • [36] Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas
    Psarras, K
    Ueda, M
    Yamamura, T
    Ozawa, S
    Kitajima, M
    Aiso, S
    Komatsu, S
    Seno, M
    [J]. PROTEIN ENGINEERING, 1998, 11 (12): : 1285 - 1292
  • [37] Targeting activated lymphocytes with an entirely human immunotoxin analogue: Human pancreatic RNase1-human IL-2 fusion
    Psarras, K
    Ueda, M
    Tanabe, M
    Kitajima, M
    Aiso, S
    Komatsu, S
    Seno, M
    [J]. CYTOKINE, 2000, 12 (06) : 786 - 790
  • [38] Ribonuclease A
    Raines, RT
    [J]. CHEMICAL REVIEWS, 1998, 98 (03) : 1045 - 1065
  • [39] Natural and engineered cytotoxic ribonucleases: Therapeutic potential
    Rybak, SM
    Newton, DL
    [J]. EXPERIMENTAL CELL RESEARCH, 1999, 253 (02) : 325 - 335
  • [40] RYBAK SM, 1991, J BIOL CHEM, V266, P21202